Brief: InflaRx Announces Commercial Launch Of Gohibic In The US For The Treatment Of Critically Ill Covid-19 Patients
21/06/2023 12:04
June 21 (Reuters) - InflaRx NV IF0G.F :
* INFLARX ANNOUNCES COMMERCIAL LAUNCH OF GOHIBIC
(VILOBELIMAB) IN
THE U.S. FOR THE TREATMENT OF CRITICALLY ILL COVID-19 PATIENTS
Source text for Eikon: ID:nGNX5gYDx1
Further company coverage: IF0G.F
((reuters.briefs@thomsonreuters.com;))
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum